Five new directors at Novelos

Novelos Therapeutics, a US-based pharmaceutical company developing drugs for the treatment and diagnosis of cancer, has announced that Dr Rock Mackie, John Neis, Dr John Niederhuber, Dr Michael Tweedle and Dr Jamey Weichert have been appointed to its board of directors, concurrent with the closing of the recently announced acquisition of Cellectar. Dr Mackie, professor of medical physics and human oncology at the University of Wisconsin, is co-founder, chairman and director of research of TomoTherapy; Mr Neis heads the healthcare practice at Venture Investors; Dr Niederhuber was a professor and director of National Cancer Institute from 2005-10, national cancer advisory board chair, grant reviewer and investigator; Dr Tweedle, professor of cancer imaging in radiology at Ohio State, is the former president of Bracco Research USA and head of diagnostics at Bristol-Myers Squibb; and Dr Weichert, Novelos’ chief scientific officer and technology founder, is an associate professor of radiology and medical physics at University of Wisconsin.